Press
releases

Biotia Gets First-Ever NY State Regulatory Approval for a Urine Infectious Disease Test Powered by Genomics and AI

Biotia, a leading innovator in genomic-based infectious disease diagnostics, announced a major milestone with New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) approval of its BIOTIA-ID Urine NGS Assay as a Laboratory Developed Test (LDT). BIOTIA-ID is the first genomics-based urine assay leveraging artificial intelligence (AI) approved by NY. Obtaining this approval is a testament to Biotia's commitment to meeting the rigorous standards set by the NYS Department of Health, which includes a thorough review of the analytical and clinical validation of the assay in Biotia's CLIA laboratory in Queens, NY. BIOTIA-ID now joins a select group of AI-powered genomic tests transforming the future of healthcare.

Pasteur Network and GeoSeeq Foundation Partner to Tackle Climate-Associated Increases in Infectious Disease

Complex global challenges are best addressed by unlocking the power of existing networks and empowering institutes anchored in local communities. This new partnership brings together Pasteur Network — a storied and unique organization covering a breadth of countries, people and public health challenges — with nonprofit GeoSeeq Foundation — an AI-powered platform for tracking emerging and circulating pathogens, microbial discovery and predictive modeling.

U.N. Hosts Climate and Health Scientists at Plenary on Vision of Future Pandemic Preparedness

Scientists urge UN for global early warning system against pandemics amid ongoing threats like SARS-CoV-2 and drug-resistant pathogens. Collaborative efforts needed to share data internationally and leverage genomics, epidemiology, satellites, and social media for analytics and predictive models.

Biotia and Partners Develop Tracking Platform to Help Prevent Public Health Crises

Biotia launches beta testing of its technology platform to identify, analyze, track, and forecast infectious disease threats globally. Partnering with key organizations, the platform integrates climate, genomic, and epidemiological data with machine learning models to better track health threats and predict future crises. Join the alpha testing community at geoseeq.com.

Biotia To Present Clinical Validation Data At IDWEEK 2022 Annual Meeting

Biotia's groundbreaking technology for detecting pathogens in urine samples will be presented at IDWeek 2022, improving diagnostics for urinary tract infections using next-generation sequencing and machine learning.

Biotia, Pioneering Pathogen Detection Company, Raises An Oversubscribed $8M Series A

Biotia secures $8M in Series A funding led by OCA Ventures to expand its genomics and AI-powered infectious disease solutions, including pathogen detection and surveillance.

Biotia Selected By MAYO Clinic Platform To Accelerate The Success Of Its AI Diagnostic Software

Biotia joins Mayo Clinic Platform's Accelerate program, leveraging its genomics and AI capabilities to address clinical challenges in infectious disease management. Access to Mayo's Discover Platform will enhance Biotia's analytics and generate transformative insights.

Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-COV-2

Twist Bioscience and Biotia receive expanded FDA EUA for their SARS-CoV-2 Next-Generation Sequencing Assay, allowing identification of viral lineages and specific genomic mutations. The assay provides comprehensive sequencing data, aiding in clinical management and tracking virus evolution.

Recent Omicron-Related COVID-19 Surge Fuels Demand For Biotia’s COVID-DX Amongst Researchers And Public Health Authorities

Biotia’s Newest Software For SARS-COV-2 Genetic Surveillance Sees Rapid Adoption By Researchers Seeking Deeper Insights

Twist Bioscience And Biotia Receive U.S. FDA Emergency Use Authorization For First Hybridization Capture-Based Next-Generation Sequencing SARS-COV-2 Assay

Leading Pathogen Detection Company Biotia Provides Chpse HIPAA Credential To Employees For HIPAA Compliance

Novel Species Of Fungi And Bacteria Found On The ISS": Biotia Hired By NASA-JPL As A Space Station Sleuth For Pathogens

Twist Bioscience And Biotia Announce Research Use Only Availability Of First Hybridization Capture-Based Next-Generation Sequencing SARS-COV-2 Assay For Characterization And Surveillance Of The Virus

Biotia, Pioneering Pathogen Detection Company, Raises $2.4M Seed Round, Expands Scientific Advisory Board

Seeking volunteers for a microbiology study focusing on various body sites

Biotia is building out our capabilities to diagnose infectious disease, conducting R&D and building our databases to improve our diagnostic capabilities. We are seeking healthy and unhealthy volunteers for a microbiology study focusing on various body sites

Biotia's Pioneering Pathogen Detection Technology Deployed At Bumrungrad International Hospital